MA15.02 Long-Term Safety and Clinical Activity Results From a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.440
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination With Chemotherapy in Asian Patients With Advanced Solid Tumors: Phase Ib Study

Targeted Oncology
Cancer ResearchOncologyPharmacology
2020English

Mp78-07 Clinical Characteristics Associated With Early Progression or Long-Term Response From the Phase Ii Imvigor210 Study: Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma

Journal of Urology
Urology
2018English

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Long-Term Safety and Efficacy of Tocilizumab in Patients With Early Rheumatoid Arthritis of Moderate or High Activity (Results of Phase Iii Multicenter Extension Clinical Study Ml28124)

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2018English

MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results From a Multicenter Study (LCMC3)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Gemcitabine Plus Carboplatin in Patients With Advanced Hepatocellular Carcinoma: Results of a Phase II Study

ISRN Oncology
2012English

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy